Ability Biologics closes its US$18 million seed funding round.
This round of financing was led by Amplitude Ventures, which was joined by Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus and Alexandria Venture Investments.
This investment will allow Ability, a pioneer in the application of generative Artificial Intelligence (AI) to the development of new biotherapy, to raise funding to support its innovation efforts. In particular, this seed funding will help produce novel, highly targeted immunomodulators and support the development of potent and selective antibody therapeutics for cancer and immune-related disorders.
A Fasken team composed of Jonathan Raizenne and Émilie Barreca advised Ability Biologics in connection with this financing transaction.
Jurisdiction
- Québec
